← Back to Screener
Genelux Corporation Common Stock (GNLX)
Price$2.93
Growth ScoreC
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-55.23%
Price vs S&P 500 (4W)-5.78%
VGM Score48.61
Market Capitalization$131.38M
All Metrics
Book Value / Share (Quarterly)$0.52
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-91.03%
Cash Flow / Share (Quarterly)$-0.63
Price vs S&P 500 (YTD)-40.96%
Net Profit Margin (TTM)-115587.50%
EPS (TTM)$-0.85
10-Day Avg Trading Volume0.16M
EPS Excl Extra (TTM)$-0.85
EPS (Annual)$-0.86
ROI (Annual)-278.46%
Cash / Share (Quarterly)$0.59
ROA (Last FY)-168.94%
Revenue Growth TTM (YoY)0.00%
EBITD / Share (TTM)$-0.87
Operating Margin (TTM)-117650.00%
Cash Flow / Share (Annual)$-0.70
P/B Ratio5.73x
P/B Ratio (Quarterly)4.73x
Net Income / Employee (Annual)$-1,285,800
Net Interest Coverage (TTM)-6.59x
ROA (TTM)-123.65%
EPS Incl Extra (Annual)$-0.86
Current Ratio (Annual)2.43x
Quick Ratio (Quarterly)3.60x
3-Month Avg Trading Volume0.19M
52-Week Price Return15.81%
Revenue / Employee (TTM)$300
Tangible BV / Share (Quarterly)$0.92
P/S Ratio (Annual)16422.80x
Asset Turnover (Annual)0.00x
52-Week High$8.54
EPS Excl Extra (Annual)$-0.86
CapEx CAGR (5Y)122.80%
26-Week Price Return-47.30%
Quick Ratio (Annual)2.34x
13-Week Price Return8.92%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.68x
Enterprise Value$122.11M
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$300
Pretax Margin (Annual)-401812.50%
Cash / Share (Annual)$0.39
3-Month Return Std Dev60.91%
Net Income / Employee (TTM)$-1,343,200
ROE (Last FY)-278.46%
Net Interest Coverage (Annual)-4.74x
EPS Basic Excl Extra (Annual)$-0.86
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.85
ROI (TTM)-174.55%
P/S Ratio (TTM)16422.80x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$-1.46
Price vs S&P 500 (52W)-8.56%
Year-to-Date Return-32.80%
5-Day Price Return-1.35%
EPS Normalized (Annual)$-0.86
ROA (5Y Avg)-130.42%
Net Profit Margin (Annual)-401812.50%
Month-to-Date Return-3.93%
Cash Flow / Share (TTM)$-1.00
EBITD / Share (Annual)$-0.89
Operating Margin (Annual)-415175.00%
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.85
P/TBV (Quarterly)12.34x
P/B Ratio (Annual)14.37x
Pretax Margin (TTM)-115587.50%
Book Value / Share (Annual)$0.31
Price vs S&P 500 (13W)0.67%
Beta0.57x
Revenue / Share (TTM)$0.00
ROE (TTM)-174.55%
52-Week Low$2.29
gGradeC
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.20est. -0.18
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.08
4.08
4.08
4.08
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GNLXGenelux Corporation Common Stock | — | C | C | $2.93 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Genelux Corp is a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies for difficult-to-treat solid tumors. The company's lead candidate, olvimulogene nanivacirepvec (Olvi-Vec), is being evaluated for lung and pancreatic cancers. The approach leverages engineered viruses to activate the patient's immune system against cancer cells.